PureTech Health noted that its Founded Entity, Vedanta Biosciences, a clinical-stage company that is developing a potential new category of oral therapies based on defined bacterial consortia, announced the publication of Phase 2 study results from its lead program, VE303, in the Journal of the American Medical Association JAMA , as well as a late-breaker oral presentation at the European Congress of Clinical Microbiology in Infectious Diseases or ECCMID, annual event. The JAMA paper, "VE303, a Defined Bacterial Consortium, vs. Placebo for the Prevention of Recurrent Clostridioides difficile Infection: A Randomized Trial," expands on the results of the Phase 2 study of VE303, which was designed to identify the recommended dose for a Phase 3 study of VE303. The study data confirmed that VE303 prevented recurrent Clostridioides difficile infection compared with placebo in the study population. The publication announced today includes new analyses of secondary efficacy endpoints, such as CDI recurrence rates at week 24, and stool microbiome endpoints, which included both VE303 strain colonization and gut microbiome diversity.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on PRTC: